Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Drugs that restore mitochondria function may treat Alzheimer's disease at early stages: Research

Before Alzheimer's patients experience memory loss, the brain's neurons have already suffered harm for years. A new study in mouse models by researchers at Columbia University Medical Center has found that the brain's mitochondria, the powerhouses of the cell, are one of the earliest casualties of the disease. The study, which appeared in the online Early Edition of PNAS, also found that impaired mitochondria then injure the neurons' synapses, which are necessary for normal brain function.

14 Oct 2010

Experts reach consensus about DBS treatment for Parkinson's disease

Since the late 1990s, deep brain stimulation (DBS) has proven to be a lifeline for some patients suffering from Parkinson's disease, a cruel neurological disorder that can cause lack of control over movement, poor balance and coordination, and rigidity, among other symptoms.

14 Oct 2010

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Ligand Pharmaceuticals Incorporated today announced that its partner Pfizer, Inc. launched Viviant® (Bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. Under the brand name Conbriza®, the drug is also marketed in Spain through a co-promotion with Almirall, an international pharmaceutical company based in Spain.

14 Oct 2010

Stimulating brain's nicotine receptors may eliminate side effects of Alzheimer's drug: Research

A team of neuroscientists has discovered important new information in the search for an effective treatment for Alzheimer's disease, the debilitating neurological disorder that afflicts more than 5.3 million Americans and is the sixth-leading cause of death in the United States. Hey-Kyoung Lee, associate professor in the University of Maryland Department of Biology, and her research team have shown that they may be able to eliminate debilitating side effects caused by a promising Alzheimer's drug by stimulating the brain's nicotine receptors.

14 Oct 2010

Walking six miles per week preserves memory in old age

New research suggests that walking at least six miles per week may protect brain size and in turn, preserve memory in old age, according to a study published in the October 13, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

14 Oct 2010

Patients with memory impairment have intact ability to hold information in mind: Research

Researchers at the University of California, San Diego School of Medicine, led by Larry R. Squire, PhD, professor of psychiatry, psychology and neurosciences at UC San Diego and a scientist at the VA San Diego Healthcare System, report that working memory of relational information where an object is located, for example remains intact even if key brain structures like the hippocampus are damaged.

13 Oct 2010

Researchers find gene association between Type 2 diabetes and Alzheimer's disease progression

Mount Sinai School of Medicine researchers have found that a gene associated with the onset of Type 2 diabetes also is found at lower-than-normal levels in people with Alzheimer's disease. The research, led by Giulio Maria Pasinetti, MD, PhD, The Saunder Family Professor in Neurology, and Professor of Psychiatry and Geriatrics and Adult Development at Mount Sinai School of Medicine, was published this month in Aging Cell.

13 Oct 2010

Adeona announces five scientific publications on Alzheimer's disease and cognitive decline

Adeona Pharmaceuticals, Inc., announced five scientific publications on the role of copper toxicity and zinc deficiency in Alzheimer's disease and cognitive decline.

12 Oct 2010

Synosia announces $30M Series C financing

Synosia Therapeutics, a privately held biotherapeutics company focused on neurology and psychiatry, today announced that it has raised $30M in a Series C financing round.

12 Oct 2010

UCB, Synosia Therapeutics announce new strategic partnership in neurology

UCB and Synosia Therapeutics announced today a new strategic partnership in neurology. Synosia has granted UCB a license for exclusive, worldwide rights to the development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications. Both are in Phase II clinical development for the treatment of Parkinson's disease.

12 Oct 2010

New microchip technology to identify neuronal regenerators

Scientists have long sought the ability to regenerate nerve cells, or neurons, which could offer a new way to treat spinal-cord damage as well as neurological diseases such as Alzheimer's or Parkinson's. Many chemicals can regenerate neurons grown in Petri dishes in the lab, but it's difficult and time-consuming to identify those chemicals that work in live animals, which is critical for developing drugs for humans.

12 Oct 2010

Embryonic stem cells used in first trial for spinal cord injury

The first ever patient to receive treatment in a U.S. government approved study involving human embryonic stem cells has been injected with millions of the potentially life saving cells. He is presently being treated at the Shepherd Center in Atlanta. He was partially paralyzed following a spinal cord injury. The center specializes in treating these types of injuries.

11 Oct 2010

New experimental vaccine against Alzheimer's disease

Researchers at UT Southwestern Medical Center have created an experimental vaccine against beta-amyloid, the small protein that forms plaques in the brain and is believed to contribute to the development of Alzheimer's disease.

11 Oct 2010

Researchers create experimental vaccine for Alzheimer's disease

11 Oct 2010

AFA quarterly magazine features President Obama as guest columnist

President Obama is featured as a guest columnist in the latest issue of the Alzheimer's Foundation of America's (AFA) quarterly magazine for caregivers of individuals with Alzheimer's disease and related illnesses, care ADvantage. In his column, he outlines important provisions in the Affordable Care Act that are relevant to the Alzheimer's community, such as health insurance, drug coverage and long-term care.

8 Oct 2010

Roskamp to initiate RCP-006 clinical trials for Alzheimer's disease

Today the Roskamp Institute said that it is pleased to announce that it will soon begin clinical trials of RCP-006, a compound found in tobacco, for the treatment of Alzheimer's disease.

8 Oct 2010

Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD

Targacept, Inc. today announced top-line results from a Phase 2 clinical trial of AZD1446 conducted by AstraZeneca in adults with attention deficit/hyperactivity disorder (ADHD).

8 Oct 2010

Elevated levels of iron in brain enhance brain-destroying plaque production in Alzheimer's patients: Research

Massachusetts General Hospital researchers say they have determined how iron contributes to the production of brain-destroying plaques found in Alzheimer's patients.

7 Oct 2010

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.

7 Oct 2010

New video PSA may help raise donation for brain research

In its continuing fight to end brain disorders, the American Academy of Neurology Foundation is turning entries submitted to the 2010 Neuro Film Festival into its latest video public service announcement about the need for donations for more research into curing brain disorders.

7 Oct 2010

Alzheimer's Disease News and Research

Further Reading

Drugs that restore mitochondria function may treat Alzheimer's disease at early stages: Research

Experts reach consensus about DBS treatment for Parkinson's disease

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Stimulating brain's nicotine receptors may eliminate side effects of Alzheimer's drug: Research

Walking six miles per week preserves memory in old age

Patients with memory impairment have intact ability to hold information in mind: Research

Researchers find gene association between Type 2 diabetes and Alzheimer's disease progression

Adeona announces five scientific publications on Alzheimer's disease and cognitive decline

Synosia announces $30M Series C financing

UCB, Synosia Therapeutics announce new strategic partnership in neurology

New microchip technology to identify neuronal regenerators

Embryonic stem cells used in first trial for spinal cord injury

New experimental vaccine against Alzheimer's disease

Researchers create experimental vaccine for Alzheimer's disease

AFA quarterly magazine features President Obama as guest columnist

Roskamp to initiate RCP-006 clinical trials for Alzheimer's disease

Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD

Elevated levels of iron in brain enhance brain-destroying plaque production in Alzheimer's patients: Research

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

New video PSA may help raise donation for brain research

Aneuro: A Year of Neuroscience in Review eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News